Based on a world-class R&D engine, Lycera has built a robust proprietary pipeline of selective immune modulators for the treatment of autoimmune diseases and cancer. Lycera is the leader in the development of agonists of RORγ, a master transcription factor, or “master control switch,” with diverse applications in immuno-oncology. In January 2017, Lycera announced the initiation of a Phase 1/2A study designed to find the biologically active or maximum tolerated dose of LYC-55716. Lycera announced in October 2017 that LYC-55716 would progress to Phase 2A development. The study will enroll approximately 75 patients in 6 tumor cohorts. Tumor cohorts were identified based on RORγ expression, biology and sensitivity to immunotherapies. Patients will be enrolled if they have failed standard therapies and have been diagnosed with advanced Non-Small Cell Lung Cancer, Squamous Cell Cancer of the Head & Neck, Ovarian Cancer, Bladder Cancer, Renal Cancer, and Gastro-esophageal Cancer. The trial is expected to be fully enrolled by mid-2018. In January 2018, Lycera announced the initiation of a multi-center Phase 1B combination study in metastatic Non-Small Cell Lung Cancer in combination with pembrolizumab. (Please click here for more information)

Lycera’s lead immune suppression program focusing on ATPase modulation originates from our deep expertise in immune metabolism, a field of biology focused on how energy is made and utilized. Unlike normal cells, disease-causing immune cells have metabolic abnormalities that sensitize them to modulation. ATPase modulators have been shown to be beneficial in several widely-accepted models for autoimmune disease, as well as in human translational systems, acting through pathways directly involved in immune regulation. (Please click here for more information)